Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia

• Published in: Cancers Vol. 13; no. 4; p. 826
• Main Authors: Kaiser, Lisa Marie, Harms, Mirja, Sauter, Daniel, Rawat, Vijay P S, Glitscher, Mirco, Hildt, Eberhard, Tews, Daniel, Hunter, Zachary, Münch, Jan, Buske, Christian
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 16.02.2021
• Subjects: CXCR4; CXCR4 antagonist; EPI-X4; Waldenström’s Macroglobulinemia
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13040826

CXCR4 expression and downstream signaling have been identified as key factors in malignant hematopoiesis. Thus, up to 40% of all patients with Waldenström's macroglobulinemia (WM) carry an activating mutation of CXCR4 that leads to a more aggressive clinical course and inferior outcome upon treatment with the Bruton's tyrosine kinase inhibitor ibrutinib. Nevertheless, little is known about physiological mechanisms counteracting CXCR4 signaling in hematopoietic neoplasms. Recently, the endogenous human peptide EPI-X4 was identified as a natural CXCR4 antagonist that effectively blocks CXCL12-mediated receptor internalization and suppresses the migration and invasion of cancer cells towards a CXCL12 gradient. Here, we demonstrate that EPI-X4 efficiently binds to CXCR4 of WM cells and decreases their migration towards CXCL12. The CXCR4 inhibitory activity of EPI-X4 is accompanied by reduced expression of genes involved in MAPK signaling and energy metabolism. Notably, the anti-WM activity of EPI-X4 could be further augmented by the rational design of EPI-X4 derivatives showing higher binding affinity to CXCR4. In summary, these data demonstrate that a naturally occurring anti-CXCR4 peptide is able to interfere with WM cell behaviour, and that optimized derivatives of EPI-X4 may represent a promising approach in suppressing growth promoting CXCR4 signaling in WM.